FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:792-794 March 21, 1996 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The treatment of Hodgkin's disease is a model of successful therapy for childhood cancer, with cure rates of over 90 percent expected from chemotherapy regimens and low-dose radiation (15 to 25 Gy) to involved regions.¹ The current therapy evolved to minimize previously recognized late effects of treatment, such as growth retardation and secondary malignant tumors. In this issue of the Journal, Bhatia et al.,² representing the Late Effects Study Group, report that second cancers developed 18 times more often in patients who received treatment for Hodgkin's disease before the age of 16 years than would be expected in the general . . . [Full Text of this Article]

References

Related Letters:

Late Effects of Treatment for Childhood Hodgkin's Disease
Mirer F. E., Ekert H., Travis L. B., Curtis R. E., Boice J. D., Bhatia S., Robison L. L., Meadows A. T., Donaldson S. S., Hancock S. L.
Extract | Full Text  
N Engl J Med 1996; 335:352-355, Aug 1, 1996. Correspondence

This article has been cited by other articles:

• Nichols, K. E., Heath, J. A., Friedman, D., Biegel, J. A., Ganguly, A., Mauch, P., Diller, L. (2003). TP53, BRCA1, and BRCA2 Tumor Suppressor Genes Are Not Commonly Mutated in Survivors of Hodgkin's Disease With Second Primary Neoplasms. JCO 21: 4505-4509 [Abstract] [Full Text]  
• Foss Abrahamsen, A., Andersen, A., Nome, O., Jacobsen, A. B., Holte, H., Foss Abrahamsen, J., Kvaloy, S. (2002). Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol 13: 1786-1791 [Abstract] [Full Text]  
• Hudson, M. M. (2002). Pediatric Hodgkin's Therapy: Time for a Paradigm Shift. JCO 20: 3755-3757 [Full Text]  
• Dores, G. M., Metayer, C., Curtis, R. E., Lynch, C. F., Clarke, E. A., Glimelius, B., Storm, H., Pukkala, E., van Leeuwen, F. E., Holowaty, E. J., Andersson, M., Wiklund, T., Joensuu, T., van't Veer, M. B., Stovall, M., Gospodarowicz, M., Travis, L. B. (2002). Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin's Disease: A Population-Based Evaluation Over 25 Years. JCO 20: 3484-3494 [Abstract] [Full Text]  
• Aisenberg, A. C., Finkelstein, D. M., van Leeuwen, F. E., Klokman, W. J., Aleman, B. M. P. (2000). Second Malignancies in Hodgkin's Disease. JCO 18: 2186-2187 [Full Text]  
• van Leeuwen, F. E., Klokman, W. J., Veer, M. B. v.’t, Hagenbeek, A., Krol, A. D. G., Vetter, U. A. O., Schaapveld, M., van Heerde, P., Burgers, J. M. V., Somers, R., Aleman, B. M. P. (2000). Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood. JCO 18: 487-487 [Abstract] [Full Text]  
• Swerdlow, A. J., Barber, J. A., Hudson, G. V., Cunningham, D., Gupta, R. K., Hancock, B. W., Horwich, A., Lister, T. A., Linch, D. C. (2000). Risk of Second Malignancy After Hodgkin’s Disease in a Collaborative British Cohort: The Relation to Age at Treatment. JCO 18: 498-498 [Abstract] [Full Text]  
• Socie, G., Curtis, R. E., Deeg, H. J., Sobocinski, K. A., Filipovich, A. H., Travis, L. B., Sullivan, K. M., Rowlings, P. A., Kingma, D. W., Banks, P. M., Travis, W. D., Witherspoon, R. P., Sanders, J., Jaffe, E. S., Horowitz, M. M. (2000). New Malignant Diseases After Allogeneic Marrow Transplantation for Childhood Acute Leukemia. JCO 18: 348-348 [Abstract] [Full Text]  
• Nichols, K. E., Levitz, S., Shannon, K. E., Wahrer, D. C.R., Bell, D. W., Chang, G., Hegde, S., Neuberg, D., Shafman, T., Tarbell, N. J., Mauch, P., Ishioka, C., Haber, D. A., Diller, L. (1999). Heterozygous Germline ATM Mutations Do Not Contribute to Radiation-Associated Malignancies After Hodgkin's Disease. JCO 17: 1259-1259 [Abstract] [Full Text]  
• Felix, C. A., Walker, A. H., Lange, B. J., Williams, T. M., Winick, N. J., Cheung, N.-K. V., Lovett, B. D., Nowell, P. C., Blair, I. A., Rebbeck, T. R. (1998). Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. USA 95: 13176-13181 [Abstract] [Full Text]  
• Deeg, H. J., Socie, G. (1998). Malignancies After Hematopoietic Stem Cell Transplantation: Many Questions, Some Answers. Blood 91: 1833-1844 [Full Text]  
• Mirer, F. E., Ekert, H., Travis, L. B., Curtis, R. E., Boice, J. D., Bhatia, S., Robison, L. L., Meadows, A. T., Donaldson, S. S., Hancock, S. L. (1996). Late Effects of Treatment for Childhood Hodgkin's Disease. NEJM 335: 352-355 [Full Text]  
• (1996). Late Breast Cancer after Childhood Hodgkin's Disease. JWatch Women's Health 1996: 22-22 [Full Text]